--- title: "Arizona APOE Cohort Study" id: "7204" type: "study" slug: "sa000058" published_at: "2024-11-27T16:17:07+00:00" modified_at: "2026-03-26T16:22:49+00:00" url: "https://dss.niagads.org/studies/sa000058/" markdown_url: "https://dss.niagads.org/studies/sa000058.md" excerpt: "Different variants of the apolipoprotein E (APOE) gene have been associated with different levels of risk for developing Alzheimer’s disease. This long-term study will gather data in cognitively normal older adults and compare cognitive, behavioral, and physical changes across different..." --- ## Description Different variants of the apolipoprotein E (APOE) gene have been associated with different levels of risk for developing Alzheimer’s disease. This long-term study will gather data in cognitively normal older adults and compare cognitive, behavioral, and physical changes across different APOE variants, or genotypes. We will develop, use, and extensively share critically important resources of cognitive, biomarker, genetic, and related data from cognitively unimpaired 50-90-year-old persons with each common form of APOE, the major Alzheimer’s disease susceptibility gene, representing six levels of risk. We will clarify the impact of APOE, other genetic and non-genetic factors, and their interactions on the predisposition to, protection from and potential prevention of Alzheimer’s disease, inform the design and size of 12 or 24-month prevention trials using biological outcome measurements, and demonstrate the value of extremely promising blood tests in these endeavors. We will provide an extensively shared resource of data, findings, biological samples, and motivated APOE-tested volunteers for the research community, support a wide range of other studies. ## PI Jessica Langbaum, PhD *Banner Alzheimer’s Institute* Eric Reiman, MD *Banner Alzheimer’s Institute* Yi Su, PhD *Banner Alzheimer’s Institute* Bryan Woodruff, MD *Mayo Clinic Arizona* ## Associated Datasets - [NG00067 - ADSP Umbrella](https://dss.niagads.org/datasets/ng00067/) This dataset includes sequencing data and harmonized phenotypes from cohorts sequenced by the Alzheimer’s Disease Sequencing Project and other AD and Related Dementia’s studies. Samples are processed using a common… [Learn more](https://dss.niagads.org/datasets/ng00067/) ## Associated Sample Sets - [snd10097 - AZAPOE WGS](https://dss.niagads.org/sample-sets/snd10097/) A total of 88 samples were sequenced at USUHS using the NovaSeq platform. The FASTQ files were sent to GCAD for processing through the VCPA1.1 pipeline. All 88 samples passed… [Learn more](https://dss.niagads.org/sample-sets/snd10097/) ## Cohorts - [Arizona APOE Cohort Study](https://dss.niagads.org/cohorts/banner-health-apoe-longitudinal/) Cognitively unimpaired 50-90-year-old persons with each common form of APOE genotype providing blood and cerebrospinal fluid samples obtained utilizing the NCRAD protocol with storage and management through NCRAD, amyloid and… [Learn more](https://dss.niagads.org/cohorts/banner-health-apoe-longitudinal/) ## Grants R01AG069453 ## Acknowledgement ### Acknowledgment statement for any data distributed by NIAGADS: Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging. ### For investigators using Arizona APOE Cohort Study data: The Arizona APOE Cohort Study is conducted by Banner Alzheimer’s Institute located in Phoenix, AZ, USA in collaboration with Mayo Clinic Arizona in Scottsdale, AZ, USA. The Arizona APOE Cohort Study is supported by funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) (R01AG069453). Research reported in this publication was also supported by the NIA under Award Number P30AG072980 to the Arizona Alzheimer’s Disease Research Center. We thank the staff and investigators of the studies as well as the participants whose help and participation made this work possible. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the funders or study team. ## Publications - Guo X. **A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease.***IEEE/ACM transactions on computational biology and bioinformatics. 2022 Sep-Oct.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/34428151/) - Chen K. **Limitations of clinical trial sample size estimate by subtraction of two measurements.***Statistics in medicine. 2022 Mar 30.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/34725853/) - Wang G. **Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry Biomarker.***Journal of Alzheimer's disease : JAD. 2022.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/34924383/) - Wu J. **Predicting Tau Accumulation in Cerebral Cortex with Multivariate MRI Morphometry Measurements, Sparse Coding, and Correntropy.***Proceedings of SPIE--the International Society for Optical Engineering. 2021 Nov.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/34961803/) - Krell-Roesch J. **Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.***Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023 Oct.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/35142047/) - Shah J. **Deep residual inception encoder-decoder network for amyloid PET harmonization.***Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022 Dec.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/35142053/) - Wu J. **INVESTIGATING THE EFFECT OF TAU DEPOSITION AND APOE ON HIPPOCAMPAL MORPHOMETRY IN ALZHEIMER'S DISEASE: A FEDERATED CHOW TEST MODEL.***Proceedings. IEEE International Symposium on Biomedical Imaging. 2022 Mar.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/36147309/) - Suchy-Dicey A. **Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study.***Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023 Jun.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/36453775/) - Wu J. **Improved Prediction of Amyloid-β and Tau Burden Using Hippocampal Surface Multivariate Morphometry Statistics and Sparse Coding.***Journal of Alzheimer's disease : JAD. 2023.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/36463452/) - Protas H. **Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum.***Frontiers in neuroscience. 2023.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/36937677/) - Malek-Ahmadi M. **Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults.***Alzheimer's research & therapy. 2023 Apr 10.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/37038190/) - Wu J. **A Surface-Based Federated Chow Test Model for Integrating APOE Status, Tau Deposition Measure, and Hippocampal Surface Morphometry.***Journal of Alzheimer's disease : JAD. 2023.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/37182882/) - Krell-Roesch J. **Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study.***Alzheimer's & dementia (Amsterdam, Netherlands). 2023 Jul-Sep.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/37529120/) - Ramos C. **Psychological Status of the Participants in Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia.***Journal of Alzheimer's disease : JAD. 2023.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/37638430/) - Kwak MG. **Self-Supervised Contrastive Learning to Predict the Progression of Alzheimer's Disease with 3D Amyloid-PET.***Bioengineering (Basel, Switzerland). 2023 Sep 28.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/37892871/) - Dong Q. **Correlation studies of Hippocampal Morphometry and Plasma NFL Levels in Cognitively Unimpaired Subjects.***IEEE transactions on computational social systems. 2023 Dec.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/38084365/) - Haney MS. **APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia.***Nature. 2024 Apr.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/38480892/)